ATS 2024 Final Program

Click on the session title to view the speakers

197

MONDAY • MAY 20

12:15 The Extracellular Matrix as a Contributor to the Hallmarks of Lung Aging 12:30 Immune Mechanisms of Lung Aging Based on Infections 12:45 Cellular Senescence, Senolytics, and Respiratory Disorders and Diseases

12:10 Radiomic Approach to Risk Stratification for Patients Undergoing Lung Cancer Screening in LPOP 12:20 Overcoming Barriers to the Integration of Smoking Cessation into Lung Cancer Screening 12:30 Lung Cancer Screening Organizational Characteristics and Program Performance in LPOP 12:40 Lung Cancer Screening for Veterans in LPOP: Measuring Real-World Benefit and Harm 12:50 Discussion, Q&A

VETERAN'S ADMINISTRATION MID-DAY SESSION

MD26 RESEARCH IN VHA’S LPOP PROVIDES IMPORTANT OPPORTUNITIES TO IMPROVE LUNG CANCER SCREENING 12:00 p.m. - 1:00 p.m. San Diego Convention Center Room 6D (Upper Level) Target Audience Providers of lung health; those interested in and/or overseeing lung cancer screening programs; those with interests in public and population health; those interested in lung cancer; those interested in interventional pulmonary medicine. Objectives At the conclusion of this session, the participant will be able to: • apply new strategies in selecting patients for lung cancer screening, such as prediction-augmented approaches. • better counsel patients who are active cigarette smokers in a screening program in the value of committing to use of aggressive approaches for smoking cessation. • describe new findings about the relationships between baseline health status and whether the patient will be likely to benefit from from lung cancer screening. Lung cancer is a leading cause of death. VHA has embarked on the Lung Precision Oncology Program (LPOP) that includes a focus on screening. Selecting patients for screening by age and cigarette smoking improves lung cancer mortality but is resource-intensive, identifies lung cancer in less than 5%, and is under used overall and possibly over used in frail patients. This session will describe research projects in LPOP that identify more efficient approaches for selection, determine how baseline health status affects outcomes, examine how cigarette smoking can be treated effectively, and evaluate impacts of program organizational structure on uptake and access. 12:00 Prediction-Augmented Approach to Patient Selection for Lung Cancer Screening in LPOP.

NHLBI, NIH MID-DAY SESSION

MD27 TRANS-OMICS FOR PRECISION

MEDICINE (TOPMED) PHASE 2: FROM WGS TO FUNCTIONAL GENOMICS

12:00 p.m. - 1:00 p.m.

San Diego Convention Center Room 8 (Upper Level)

Target Audience The target audience will include researchers, physicians, and vendors that are interested in molecular and cellular basis of lung diseases and precision medicine. Objectives At the conclusion of this session, the participant will be able to: • understand the progress report of TOPMed as a resource for genomics study • learn from omics data on aging, gender, and lung diseases. • understand recent progress in the discovery of genetic basis of common, complex diseases like COPD and IPF. NHLBI’s Trans-Omics for Precision Medicine (TOPMed) is to create a large genomic dataset supporting research communities’ efforts on precision medicine. In Its first phase, TOPMed has generated 200,000 whole genome sequencing (WGS) data. Starting its second phase, TOPMed is moving toward the functional genomics and will generate 270,000 multi-omics data (RNA-seq, methylome, metabolome, and proteome). Overall, this session aims to showcase the work of TOPMed as a community resource for precision medicine research. It will highlight the diverse applications of TOPMed data in studying asthma, COPD, and IPF, and emphasize the potential for improving diagnosis, treatment, and prevention strategies in these respiratory conditions.

ATS 2024 Conference Program • San Diego, CA